Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$7.61
-0.1%
$7.66
$3.68
$8.85
$285.05M0.65112,629 shs68,020 shs
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.74
-7.0%
$1.97
$1.23
$4.92
$70.19M-0.12303,231 shs281,043 shs
Moderna, Inc. stock logo
MRNA
Moderna
$24.09
-1.6%
$29.09
$23.15
$79.96
$9.52B1.839.44 million shs8.27 million shs
Neurogene Inc. stock logo
NGNE
Neurogene
$18.48
-1.9%
$20.38
$6.88
$74.49
$268.89M1.69111,648 shs94,969 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-0.13%+0.13%+7.03%+15.13%+91.69%
Metagenomi, Inc. stock logo
MGX
Metagenomi
-6.95%-9.84%-23.35%+2.94%-42.19%
Moderna, Inc. stock logo
MRNA
Moderna
-1.55%-11.17%-25.07%-9.30%-69.26%
Neurogene Inc. stock logo
NGNE
Neurogene
-1.91%-7.55%-15.50%+7.38%-48.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
0.766 of 5 stars
1.30.00.00.02.63.30.6
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.2855 of 5 stars
3.52.00.00.02.11.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.494 of 5 stars
4.02.00.04.62.72.50.6
Neurogene Inc. stock logo
NGNE
Neurogene
2.3634 of 5 stars
3.40.00.00.03.41.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
2.67
Moderate Buy$8.005.12% Upside
Metagenomi, Inc. stock logo
MGX
Metagenomi
3.00
Buy$10.00474.71% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$42.8878.01% Upside
Neurogene Inc. stock logo
NGNE
Neurogene
2.75
Moderate Buy$46.17149.82% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, NGNE, and LFCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $15.00
8/19/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
8/15/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
8/14/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$32.00
7/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$26.00 ➝ $25.00
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$128.87M2.21N/AN/A$0.04 per share190.25
Metagenomi, Inc. stock logo
MGX
Metagenomi
$52.29M1.25N/AN/A$5.22 per share0.33
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B2.90N/AN/A$24.16 per share1.00
Neurogene Inc. stock logo
NGNE
Neurogene
N/AN/AN/AN/A$19.15 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$78.06M-$2.36N/AN/AN/A-257.99%-37.84%-27.15%11/12/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Neurogene Inc. stock logo
NGNE
Neurogene
-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)

Latest MGX, MRNA, NGNE, and LFCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.68-$0.54+$0.14-$0.54$7.72 million$8.51 million
8/11/2025Q2 2025
Neurogene Inc. stock logo
NGNE
Neurogene
-$1.15-$1.05+$0.10-$1.05N/AN/A
8/7/2025Q4 2025
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Neurogene Inc. stock logo
NGNE
Neurogene
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
113.76
2.84
1.77
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
6.36
6.36
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Neurogene Inc. stock logo
NGNE
Neurogene
N/A
18.07
18.07

Institutional Ownership

CompanyInstitutional Ownership
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Neurogene Inc. stock logo
NGNE
Neurogene
52.37%

Insider Ownership

CompanyInsider Ownership
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
32.20%
Metagenomi, Inc. stock logo
MGX
Metagenomi
17.80%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Neurogene Inc. stock logo
NGNE
Neurogene
11.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
69037.41 million25.36 millionOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
23637.53 million30.85 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
Neurogene Inc. stock logo
NGNE
Neurogene
9014.27 million12.61 millionOptionable

Recent News About These Companies

Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.17
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
Neurogene (NGNE) to Release Earnings on Friday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lifecore Biomedical stock logo

Lifecore Biomedical NASDAQ:LFCR

$7.61 -0.01 (-0.13%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$7.61 +0.00 (+0.01%)
As of 08/29/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.74 -0.13 (-6.95%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.81 +0.07 (+4.02%)
As of 08/29/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$24.09 -0.38 (-1.55%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$24.16 +0.07 (+0.29%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Neurogene stock logo

Neurogene NASDAQ:NGNE

$18.48 -0.36 (-1.91%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$18.47 -0.01 (-0.05%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.